Prolia Approved by FDA for Treatment of Glucocorticoid-Induced Osteoporosis
Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.
Officials with the FDA have approved the use of denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis (GIOP), according to a press release. The treatment is indicated for men and women at high risk of fracture, defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available therapies.
The approval is based on data from 12-month analysis of a 24-month, phase 3 trial evaluating the safety and efficacy of denosumab. According to the findings, patients on glucocorticoid therapy who received denosumab had greater gains in bone mineral density (BMD) compared with those who received active comparator risedronate.
Denosumab 60 mg was administered subcutaneously every 6 months compared with oral risedronate 5 mg once daily in 795 patients receiving glucocorticoid treatment, greater than or equal to 7.5 mg/day oral prednisone, or equivalent, according to the study.
“Patients on long-term systemic glucocorticoid medications can experience a rapid reduction in bone mineral density within a few months of beginning treatment,” Kenneth F Saag, MD, MSc, study lead, said in a statement. “With this approval, patients who receive treatment with glucocorticoids now have a new option to help improve their bone mineral density.”
For additional information, visit SpecialtyPharmacyTimes.com.
Reference
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis [news release]. Amgen’s website. https://www.amgen.com/media/news-releases/2018/05/fda-approves-prolia-denosumab-for-glucocorticoidinduced-osteoporosis/. Accessed May 22, 2018.
